Predominant role of the Fab fragment in delaying hyperacute rejection in guinea pig-to-rat xenotransplantation

Transplantation

Volumn 66, Issue 3, 1998, Pages 395-397

  Urbani, Lucio ^a   Fabre, Monique ^b   Cardoso, Jorge ^a   Lambin, Patrick ^c   Devillier, Philippe ^d   Soubrane, Olivier ^a   Houssin, Didier ^a   Gautreau, Chantal ^a,e  

^a UNIVERSITÉ PARIS DESCARTES   (France)

^b BICÊTRE HOSPITAL   (France)

^c INSTITUT NATIONAL DE LA TRANSFUSION SANGUINE   (France)

^d REIMS UNIVERSITY HOSPITAL   (France)

^e Institut Cochin   (France)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN F(AB) FRAGMENT; IMMUNOGLOBULIN G;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; EDEMA; GRAFT REJECTION; GRAFT SURVIVAL; GUINEA PIG; NECROSIS; NONHUMAN; PRIORITY JOURNAL; RAT; ST SEGMENT; SURVIVAL TIME; XENOTRANSPLANTATION;

EID: 0032529655     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007890-199808150-00018     Document Type: Article

References (13)

1. Leventhal JR, Dalmasso AP, Cromwell JW, et al. Prolongation of cardiac xenograft survival by depletion of complement. Transplantation 1993; 55: 857.
2. Leventhal JR, Matas AJ, Sun LH, et al. The immunopathology of cardiac xenograft rejection in the guinea pig-to-rat model. Transplantation 1993; 56: 1.
3. Gambiez L, Salame E, Cherreau C, et al. The role of human natural IgM in the hyperacute rejection of discordant heart xenografts. Transplantation 1992; 54: 577.
4. Gautreau C, Kojima T, Woimant G, et al. Use of intravenous immunoglobulin to delay xenogeneic hyperacute rejection. Transplantation 1995; 60: 903.
5. Magee JC, Collins BH, Harland RC, et al. Immunoglobulin prevents complement-mediated hyperacute rejection in swine-to-primate xenotransplantation. J Clin Invest 1995; 96: 2404.
6. Ono K, Lindsey ES. Improved technique of heart transplantation in rats. J Thorac Cardiovasc Surg 1969; 57: 225.
7. Schussler O, Latremouille C, Genevaz D, Carpentier A, Glotz D. Normal human polyclonal immunoglobulins for intravenous use contain anti-idiotypes against natural xenophile antibodies and prolong discordant xenograft survival. Transplant Proc 1997; 29: 959.
8. Basta M, Kirshbom P, Frank MM, Fries LF. Mechanism of therapeutic effect on high-dose intravenous immunoglobulin: attenuation of acute, complement-dependent immune damage in a guinea pig model. J Clin Invest 1989; 84: 1974.
9. Fries LF, Gaither TA, Hammer CH, Frank MM. C3b covalently bound to IgG demonstrates a reduced rate of inactivation by factors H and I. J Exp Med 1984; 160: 1640.
10. Gadd KJ, Reid KBM. The binding of complement component C3 to antibody-antigen aggregates after activation of the alternative pathway in human serum. Biochem J 1981; 195; 471.
11. Frank MM, Basta M, Fries LF. The effect of intravenous immune globulin on complement-dependent immune damage of cells and tissues. Clin Immunol Immunopathol 1992; 62: S82.
12. Kojima T, Hayashi S, Yokoyama I, Takagi H. Role of Fc fragments in inhibition of xenogeneic hyperacute rejection by intravenous immunoglobulin. Transplantation 1996; 62: 559.
13. Latremouille C, Genevaz D, Hu MC, et al. Normal human immunoglobulins for intravenous use (IVIg) delay hyperacute xenograft rejection through F(ab′)2-mediated anti-complement activity. Clin Exp Immunol 1997; 110: 122.